{"id":525793,"date":"2021-08-10T07:04:05","date_gmt":"2021-08-10T11:04:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/"},"modified":"2021-08-10T07:04:05","modified_gmt":"2021-08-10T11:04:05","slug":"foghorn-therapeutics-provides-second-quarter-2021-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/","title":{"rendered":"Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>&#8212; First Patients Dosed in Phase 1 Clinical Trials of FHD-286, an Inhibitor of BRG1\/BRM, in Metastatic Uveal Melanoma and Relapsed or Refractory Acute Myeloid Leukemia (AML)<\/em><br \/>\n        \n      <\/p>\n<p align=\"center\">\n        <em>&#8212; IND Clearance for FHD-609 Received; Sites for Phase 1 Study in Synovial Sarcoma Initiated<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>&#8212;\u00a0Continued Advancement of Broad Therapeutic Pipeline that Includes Protein Degraders, Enzymatic Inhibitors and Transcription Factor Disruptors Targeting the Chromatin Regulatory System<\/em>\n      <\/p>\n<p align=\"justify\">CAMBRIDGE, Mass., Aug.  10, 2021  (GLOBE NEWSWIRE) &#8212; Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today provided a corporate update in conjunction with the Company\u2019s From 10-Q filing for the quarter ended June 30, 2021. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control Platform\u00ae and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.<\/p>\n<p align=\"justify\">\u201cWe continue to make solid progress advancing our two first-in-class clinical programs to emerge from our proprietary Gene Traffic Control Platform,\u201d said Adrian Gottschalk, President and Chief Executive Officer. \u201cWe anticipate having initial phase I data of FHD-286, our selective, oral inhibitor of BRG1\/BRM in metastatic uveal melanoma and relapsed or refractory AML and myelodysplastic syndromes (MDS),\u00a0as early as the fourth quarter of 2021, and phase I data of FHD-609, our first protein degrader clinical candidate, for the treatment of synovial sarcoma as early as the first half of 2022.\u201d<\/p>\n<p align=\"justify\">Continued Mr. Gottschalk, \u201cBeyond these two clinical programs, we continue to expand our robust pipeline of precision therapeutic candidates targeting different aspects of the chromatin regulatory system, including our protein degrader programs and platform, including FHD-609, our BRM-selective degrader, ARID1B protein degrader and other undisclosed programs.\u201d<\/p>\n<p>\n        <strong>Recent Corporate Highlights:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt;text-align:justify\">\n          <strong>Dosed First Patient with FHD-286<\/strong>. In May 2021, Foghorn announced the dosing of the first patient in its first-in-human clinical trial of FHD-286, an inhibitor of BRG1\/BRM, in metastatic uveal melanoma and relapsed or refractory AML and MDS, areas of high unmet medical need. This is Foghorn\u2019s first drug candidate to enter the clinic and the first of a new class of therapeutics directly targeting the chromatin regulatory system. To learn more about these studies please visit\u00a0<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04879017?term=NCT04879017&amp;draw=2&amp;rank=1\" rel=\"nofollow noopener\" target=\"_blank\">ClinicalTrials.gov<\/a>. (Link <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04879017?term=NCT04879017&amp;draw=2&amp;rank=1\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a> for metastatic uveal melanoma and <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04891757?term=Foghorn&amp;draw=2\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a> for AML and MDS)<\/li>\n<li style=\"margin-bottom:12pt;text-align:justify\">\n          <strong>Received investigational new drug application (IND) clearance\u00a0for FHD-609<\/strong>.\u00a0Foghorn received FDA clearance of its IND application for FHD-609. FHD-609 is a highly potent, selective, intravenous, small molecule protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma with the intention to expand into additional indications, including SMARCB1 deleted tumors. Sites for the phase 1 study have been initiated and are currently screening patients. To learn more about this study, please visit\u00a0<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04965753?term=foghorn&amp;draw=2&amp;rank=1\" rel=\"nofollow noopener\" target=\"_blank\">ClinicalTrials.gov<\/a>.<\/li>\n<li style=\"margin-bottom:12pt;text-align:justify\">\n          <strong>BRM Selective Inhibitor Program Advanced to Lead Optimization. <\/strong>Data presented during Foghorn\u2019s 2021 Research &amp; Development Webinar demonstrated robust tumor growth inhibition with the Company\u2019s BRM-selective inhibitor. The program has advanced into lead optimization with an IND planned for 2022.<\/li>\n<li style=\"margin-bottom:12pt;text-align:justify\">\n          <strong>Participation at AACR 2021<\/strong>. In April 2021, Foghorn presented a poster titled \u201c<em>Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers\u201d <\/em>(Link to poster <a href=\"https:\/\/foghorntx.com\/wp-content\/uploads\/2021\/04\/2021_AACR_Foghorn-Poster_v5-approved.pdf\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>) and chaired a panel at the American Association for Cancer Research (AACR) Annual Meeting 2021. Key highlights of the data presented included a novel series of compounds discovered and developed by Foghorn that potently and selectively inhibit the ATPase components of the BAF complex, BRG1 and BRM. These preclinical data provided the foundation for first-in-human studies of BAF ATPase inhibition as a novel therapeutic to treat uveal melanoma.<\/li>\n<li style=\"margin-bottom:12pt;text-align:justify\">\n          <strong>Appointed Ian Smith to Board of Directors<\/strong>. On April 27<sup>th<\/sup>, 2021, Foghorn appointed Ian Smith to its Board of Directors, adding a diverse skill set spanning decades as a proven biotechnology leader. The addition of Ian to the Board brings significant business development and capital formation expertise to Foghorn.<\/li>\n<li style=\"margin-bottom:12pt;text-align:justify\">\n          <strong>Held First Research and Development Day Webinar<\/strong>. On June 15<sup>th<\/sup>, 2021, Foghorn held its inaugural Research and Development Day Webinar showcasing presentations from key opinion leaders and the Foghorn management team highlighting the biological importance of the chromatin regulatory system in gene expression and human disease and its broad applicability in precision oncology. The replay can be accessed <a href=\"https:\/\/lifesci.rampard.com\/WebcastingAppv5\/Events\/Registration\/registration.jsp?Y2lk=MTIyMg==\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>.<\/li>\n<\/ul>\n<p>\n        <strong>Key Upcoming Milestones:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt;text-align:justify\">\n          <strong>FHD-286 data<\/strong>. Foghorn expects initial data from the Company\u2019s phase 1 studies of FHD-286 in both metastatic uveal melanoma and relapsed\/refractory AML and MDS as early as the fourth quarter of 2021.<\/li>\n<li style=\"margin-bottom:12pt;text-align:justify\">\n          <strong>FHD-609 data<\/strong>. Foghorn expects initial data from the Company\u2019s phase 1 study in synovial sarcoma as early as the first half of 2022.<\/li>\n<\/ul>\n<p>\n        <strong>Upcoming Events<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt;text-align:justify\">\n          <strong>The Wedbush PacGrow Healthcare Virtual Conference<\/strong>, panel discussion, \u201cBullseye \u2013 Targeted Oncology Part 2,\u201d Wednesday, August 11 at 10:20 a.m. ET. The webcast can be accessed <a href=\"https:\/\/wsw.com\/webcast\/wedbush39\/register.aspx?conf=wedbush39&amp;page=panel16&amp;url=https%3A\/\/wsw.com\/webcast\/wedbush39\/panel16\/2580370\" rel=\"nofollow noopener\" target=\"_blank\"><u>here<\/u><\/a>.<\/li>\n<li style=\"margin-bottom:12pt;text-align:justify\">\n          <strong>The Morgan Stanley Global Healthcare Conference<\/strong>, September 13-15, 2021.<\/li>\n<\/ul>\n<p>\n        <strong>Financial Condition<\/strong>\n      <\/p>\n<p>Foghorn reported cash, cash equivalents and marketable securities of $141.3 million as of June 30, 2021, as compared to $160.9 million as of March 31, 2021, and $185.8 million as of December 31, 2020.<\/p>\n<p>\n        <strong>About Foghorn Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Foghorn\u00ae Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control\u00ae platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d regarding the Company\u2019s clinical programs for FHD-286 and FHD-609 and the Company\u2019s research pipeline. Forward-looking statements include statements regarding the Company\u2019s clinical trial, product candidates and research efforts and other statements identified by words such as \u201ccould,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201clikely,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cseeks,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201ccontinues,\u201d \u201cprojects\u201d and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risk regarding the timing of filing an IND for our product candidates and other factors set forth under the heading \u201cRisk Factors\u201d in the Company\u2019s Form 10-K. Any forward-looking statement made in this press release speaks only as of the date on which it is made.<\/p>\n<p>\n        <strong>Media Contact:<\/strong>\n      <\/p>\n<p>Fanny Cavali\u00e9, Foghorn Therapeutics Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YaKqeC6ReCnGapLjm6tpRN2hoyBb_QVhbU2jf2u4aWj9bvII4bQ1YwCHtK9LtQFMjuli48g6g83WST7m2lIXPxw6P7ZQ-uY9kSShSmp7R1E=\" rel=\"nofollow noopener\" target=\"_blank\">fcavalie@foghorntx.com<\/a><\/p>\n<p>Gregory Kelley, Ogilvy<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ILMY6CBsPUzGNSOoo5_n6N9fxmH60_8VfIflEOBekbQKqzVXLYXWfcBBH5ZrCI7JSAp-SYiNkLMcWUFIscQdGJYaf9-9eo_zdvKuzHK3qHw=\" rel=\"nofollow noopener\" target=\"_blank\">gregory.kelley@ogilvy.com<\/a><\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong>\n      <\/p>\n<p>Ben Strain, Foghorn Therapeutics Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xGn2Vbdz4aLqBHUVlAO4xbaGBFGw9HaN1iETroprBmNIbwnqQk1OksO7taq1zd7eqx2az07WDXBPqeey5W0Sm3Ce8Z3DXra6NhFHrBLXdUY=\" rel=\"nofollow noopener\" target=\"_blank\">bstrain@foghorntx.com<\/a><\/p>\n<p>Hans Vitzthum, LifeSci Advisors<br \/>617-430-7578<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AOWFSt5qkP9kfaJwTDdsv4oLczWMBP4E_V30LQVSXrihegJ9qvZEraHSWWEE0vT_538jhTKwvg_Q5GoHMYH_2S8pMJ84sQ37_Y2w61QlwsA=\" rel=\"nofollow noopener\" target=\"_blank\">hans@lifesciadvisors.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTgzMCM0MzQ5NTk3IzIyMDI4NjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YTUxYzUyMWYtNGU3ZC00ZGFlLWEwMDAtZTNhYThlN2JhYzBlLTEyMTQ0MTU=\/tiny\/Foghorn-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8212; First Patients Dosed in Phase 1 Clinical Trials of FHD-286, an Inhibitor of BRG1\/BRM, in Metastatic Uveal Melanoma and Relapsed or Refractory Acute Myeloid Leukemia (AML) &#8212; IND Clearance for FHD-609 Received; Sites for Phase 1 Study in Synovial Sarcoma Initiated &#8212;\u00a0Continued Advancement of Broad Therapeutic Pipeline that Includes Protein Degraders, Enzymatic Inhibitors and Transcription Factor Disruptors Targeting the Chromatin Regulatory System CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) &#8212; Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today provided a corporate update in conjunction with the Company\u2019s From 10-Q filing for the quarter ended June 30, 2021. With an &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-525793","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8212; First Patients Dosed in Phase 1 Clinical Trials of FHD-286, an Inhibitor of BRG1\/BRM, in Metastatic Uveal Melanoma and Relapsed or Refractory Acute Myeloid Leukemia (AML) &#8212; IND Clearance for FHD-609 Received; Sites for Phase 1 Study in Synovial Sarcoma Initiated &#8212;\u00a0Continued Advancement of Broad Therapeutic Pipeline that Includes Protein Degraders, Enzymatic Inhibitors and Transcription Factor Disruptors Targeting the Chromatin Regulatory System CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) &#8212; Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today provided a corporate update in conjunction with the Company\u2019s From 10-Q filing for the quarter ended June 30, 2021. With an &hellip; Continue reading &quot;Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-10T11:04:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTgzMCM0MzQ5NTk3IzIyMDI4NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update\",\"datePublished\":\"2021-08-10T11:04:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\\\/\"},\"wordCount\":1118,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTgzMCM0MzQ5NTk3IzIyMDI4NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\\\/\",\"name\":\"Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTgzMCM0MzQ5NTk3IzIyMDI4NjI=\",\"datePublished\":\"2021-08-10T11:04:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTgzMCM0MzQ5NTk3IzIyMDI4NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNTgzMCM0MzQ5NTk3IzIyMDI4NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update - Market Newsdesk","og_description":"&#8212; First Patients Dosed in Phase 1 Clinical Trials of FHD-286, an Inhibitor of BRG1\/BRM, in Metastatic Uveal Melanoma and Relapsed or Refractory Acute Myeloid Leukemia (AML) &#8212; IND Clearance for FHD-609 Received; Sites for Phase 1 Study in Synovial Sarcoma Initiated &#8212;\u00a0Continued Advancement of Broad Therapeutic Pipeline that Includes Protein Degraders, Enzymatic Inhibitors and Transcription Factor Disruptors Targeting the Chromatin Regulatory System CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) &#8212; Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today provided a corporate update in conjunction with the Company\u2019s From 10-Q filing for the quarter ended June 30, 2021. With an &hellip; Continue reading \"Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-10T11:04:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTgzMCM0MzQ5NTk3IzIyMDI4NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update","datePublished":"2021-08-10T11:04:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/"},"wordCount":1118,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTgzMCM0MzQ5NTk3IzIyMDI4NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/","name":"Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTgzMCM0MzQ5NTk3IzIyMDI4NjI=","datePublished":"2021-08-10T11:04:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTgzMCM0MzQ5NTk3IzIyMDI4NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNTgzMCM0MzQ5NTk3IzIyMDI4NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-second-quarter-2021-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/525793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=525793"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/525793\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=525793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=525793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=525793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}